US company unveils AI-designed, longevity-focused GLP-1 program

Longevity just got a new playbook. US-based MindWalk Holdings, the Bio-Native AI upstart, is doubling down on GLP-1 drugs — but not the ones you've seen plastered across billboards. Their latest move? A dual-pathway regimen that pairs GLP-1 receptor agonists with a proprietary companion therapeutic to supercharge healthy aging.

Think of it as taking a blockbuster class of drugs (Ozempic, Wegovy, Mounjaro) and giving them a sidekick that unlocks a whole new layer of biology. "We're not simply iterating on existing drugs," CEO Dr. Jennifer Bath told me. "We're uncovering first principles that enable the design of safe, durable GLP-1 analogs and a proprietary companion therapeutic that acts through a complementary longevity pathway."

Translation: they're rewriting the rules of longevity medicine.

How does it work?

Here's where it gets fun — and a little sci-fi.

• AI-first design: MindWalk uses LensAI, its explainable discovery engine, to map out biological cause-and-effect, not just correlations.
• Hidden biology unlocked: LensAI found a second, previously overlooked pathway that works in tandem with GLP-1 to support metabolic balance, cellular resilience, and inflammation control.
• Custom-built therapeutic: Instead of repurposing an existing drug, MindWalk built its own companion molecule to co-administer with its AI-optimized, long-acting GLP-1 analogs.

All of this is done in silico — computationally — which is faster, cheaper, and more precise than old-school lab-only drug hunting. And yes, the platform maintains a comprehensive paper trail, ensuring regulators are not concerned about the "AI-designed drug" label.

Why does it matter?

This isn't just about better weight-loss shots. It's about healthspan — living longer and better.

• More effective and durable: The combination is engineered for chronic, preventive use — a crucial factor for therapies meant to be taken for years.
• Market shake-up: Longevity therapeutics are forecasted to be a $60B industry by 2030. MindWalk is positioning itself to grab a seat at that table early.
• Proof that AI can deliver: Their earlier GLP-1 candidates already matched semaglutide in receptor assays. This dual-pathway move demonstrates that the platform can achieve more than one-hit wonders.

As CTO Dr. Dirk Van Hyfte put it: "This announcement reflects the scalability of MindWalk's Bio-Native AI platform and its ability to address high-value therapeutic categories with speed and scientific rigor." In other words, they've got a pipeline, not just a product.

The context

GLP-1 drugs are having a cultural moment. They've gone from diabetes meds to Hollywood's favorite "skinny shot" to front-page health disruptors. But their potential beyond weight loss is where things get truly interesting.

MindWalk's approach layers longevity science on top of an already proven mechanism, aiming to extend the benefits beyond weight management — into inflammation, stress response, and cellular health. It's a play that could reset our perspective on aging itself.

And they're not stopping at GLP-1. The same HYFT-powered engine is being applied to oncology, immunology, and vaccine design — essentially, wherever conserved biology can be leveraged into a druggable insight. If it works as advertised, MindWalk could be one of the first to make AI-native drug discovery more than just a buzzword.